API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
Details:
Avion Pharmaceuticals gets exclusive rights to relaunch Cenestin® in the USA. Cenestin® is the only plant-derived mixture of nine conjugated estrogens indicated for treatment of moderate to severe symptoms of vasomotor, and vulvar and vaginal atrophy due to menopause.
Lead Product(s): Conjugated Estrogens
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cenestin
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avion Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 12, 2020